46 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
of potentially best-in-class small molecule drug candidates. In particular, we demonstrated positive safety, tolerability, and antiviral activity data … after dosing for up to 64 weeks with our hepatitis B virus capsid assembly modulator, ALG-000184, and positive safety and PK data for our ritonavir-free
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
of the study and is due to start soon in the multiple ascending dose portion. We continue to project having topline data from this important safety … continues to project having topline data from this safety and pharmacokinetics study in H1 2024, that the plan is to initiate Phase 2 enabling activities
8-K
EX-10.1
zpvvip0oztl9x5g
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-99.1
68w 2ljr3whe
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
3pbmwmb3g
2 Nov 22
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
v14b3 dxzi7nf3k9o5
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
8-K
9jdgt9
22 Mar 22
Other Events
8:23am
8-K
EX-99.1
573vu8 o9as6rm7ty
10 Mar 22
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
4:05pm
8-K
6iusk1t6q1
6 Jan 22
Other Events
8:11am
S-3
EX-1.2
p7pzsk tx5b
4 Nov 21
Shelf registration
4:57pm